Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Grows By 48.0%

Evaxion Biotech A/S (NASDAQ:EVAX) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 86,700 shares, a growth of 48.0% from the February 13th total of 58,600 shares. Approximately 8.2% of the company’s stock are short sold. Based on an average daily volume of 2,250,000 shares, the days-to-cover ratio is currently 0.0 days.

Evaxion Biotech A/S Stock Performance

Shares of NASDAQ EVAX traded up $0.11 during trading on Monday, reaching $1.89. 54,723 shares of the company traded hands, compared to its average volume of 593,088. The firm has a 50 day simple moving average of $2.86 and a 200-day simple moving average of $8.19. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The stock has a market capitalization of $2.21 million, a PE ratio of -1.30 and a beta of -0.25. Evaxion Biotech A/S has a 52-week low of $1.70 and a 52-week high of $22.05.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EVAX has been the topic of several recent analyst reports. Lake Street Capital cut their price objective on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research report on Thursday, February 20th.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.